INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines – ERAS

Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Erasca and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until August 10, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Erasca securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com . On April 27, 2026, at 8:31 a.m. EDT before the market opened, Erasca disclosed receipt of a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”) alleging that Erasca’s ERAS-0015 infringes a RevMed patent (U.S. Patent No. 12,409,225) and is connected to alleged trade secret misappropriation. RevMed also alleged that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.” Erasca stated that it believes the assertions are without merit and intends to contest the allegations. On this news, Erasca’s stock price fell $2.34 per share, or 10.71%, to close at $19.50 per share on April 27, 2026.